Examining Ben Carson’s Dietary Supplement Ties
The Washington Post looks into why some conservatives aren't more skeptical of the neurosurgeon's ties to Mannatech. Elsewhere, STAT reports on the GOP presidential hopeful's record on "death panels." And Hillary Clinton supports moving medical marijuana out of schedule 1 drug status.
The Washington Post:
Why Conservatives Listen To Carson’s Pitch Of Dietary Supplements
The last time Ben Carson stepped onto a debate stage, he was asked about something he had never really questioned. Why had he endorsed the nutritional products of Mannatech, a Texas-based company that was forced to settle a 2009 wrongful marketing lawsuit? What did that endorsement say about his “judgment”? ... Yet, in defiance of the facts, Carson professed ignorance on the debate stage about any “relationship” with the company. He spent two days following the debate denouncing the questions about Mannatech as “propaganda.” And his most ardent supporters don’t care. (Weigel, 11/7)
STAT News:
Does Ben Carson Remarks Echo Controversy Over 'Death Panels'?
Does Ben Carson have a “death panels” problem? Before he was a 2016 presidential candidate, Carson, a retired neurosurgeon, frequently raised questions about the high cost of end-of-life medical care — and asked whether patients should be able to pursue every available treatment. The statements touched on many of the most sensitive questions about care for the elderly. (Nather and Swetlitz, 11/8)
The Washington Post:
Clinton Joins Democratic Rivals In Backing Change To Marijuana Classification
Hillary Rodham Clinton has long declined to endorse legalized medical or recreational marijuana at the federal level, but on Saturday, she added more specifics to her proposal to increase research into medical marijuana. Clinton said that she supports removing marijuana from a list of schedule 1 drugs, a classification that prevents federally-sponsored research into its effects. As a schedule 1 drug, marijuana is classified among the most dangerous drugs that the federal Drug Enforcement Agency regulates. (Phillip, 11/7)
